Parra-Rojas Susell, Cassol Spanemberg Juliana, Del Mar Díaz-Robayna Nerea, Peralta-Mamani Mariela, Velázquez Cayón Rocío Trinidad
Oral Medicine and Phototherapy Research Group-OMEP, Faculty of Health Sciences, Department of Dentistry, Fernando Pessoa Canary Islands University, 35450 Las Palmas, Gran Canaria, Spain.
Faculty of Health Sciences, Department of Dentistry, Fernando Pessoa Canary Islands University, 35450 Las Palmas, Gran Canaria, Spain.
Biomedicines. 2024 Oct 16;12(10):2366. doi: 10.3390/biomedicines12102366.
We report on the cost-effectiveness of photobiomodulation (PBM) for the prevention and treatment of oral mucositis (OM) derived from the cytotoxic effects of antineoplastic therapy.
This review followed the PRISMA 2020 guidelines. A search was conducted in PubMed, Scopus, Web of Science, Embase, and OpenGrey. Articles published before 23 July 2024, were included. Randomized controlled trials (RCTs) that included patients with head and neck cancer undergoing chemotherapy and/or radiotherapy and a placebo group compared to an intervention group (PBM) were selected. The risk of bias was evaluated using the Joanna Briggs Institute tools. The certainty of the evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach and was rated as moderate.
A total of 3 RCTs and 229 patients were included. PBM may represent an additional cost in the short term, but the incremental expenses derived from the cytotoxic effects of antineoplastic therapy are greater in the medium-long term. The intervention group (PBM) showed a lower incidence of severe OM compared to the control group (placebo).
PBM is a cost-effective long-term treatment, effective in preventing severe OM and improving the quality of life of cancer patients. More RCTs following the same standardized protocols are needed (registration CDR42024498825).
我们报告了光生物调节（PBM）在预防和治疗抗肿瘤治疗细胞毒性作用所致口腔黏膜炎（OM）方面的成本效益。
本综述遵循PRISMA 2020指南。在PubMed、Scopus、科学网、Embase和OpenGrey中进行了检索。纳入了2024年7月23日前发表的文章。选择了随机对照试验（RCT），这些试验纳入了接受化疗和/或放疗的头颈癌患者，以及与干预组（PBM）相比的安慰剂组。使用乔安娜·布里格斯研究所工具评估偏倚风险。使用推荐分级评估、制定和评价（GRADE）方法评估证据的确定性，并评为中等。
共纳入3项RCT和229例患者。PBM在短期内可能会带来额外成本，但从中长期来看，抗肿瘤治疗细胞毒性作用产生的增量费用更高。与对照组（安慰剂）相比，干预组（PBM）严重OM的发生率较低。
PBM是一种具有成本效益的长期治疗方法，可有效预防严重OM并提高癌症患者的生活质量。需要更多遵循相同标准化方案的RCT（注册号CDR42024498825）。
